Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age
Daniel González(University of North Carolina at Chapel Hill), Michael Cohen‐Wolkowiez(Duke University), Varsha Bhatt‐Mehta(University of Toledo Medical Center), Sailaja Puttagunta(3D Biomatrix (United States)), Xilla T. Ussery(University of North Carolina at Chapel Hill), John S. Bradley(Rady Children's Hospital-San Diego), Kevin Watt(University of Utah), Michael W. Dunne(University of North Carolina at Chapel Hill), Laura P. James(University of Arkansas for Medical Sciences), Li Zhang(China Tobacco), Jennifer Murphy(Clinical Research Institute), Jeffrey L. Blumer(University of Toledo), Janice E. Sullivan(University of Louisville), Debra L. Palazzi(Baylor College of Medicine), Ram Yogev(Northwestern University)
Cited by 6
Related Papers
Natural selection on <i>EPAS1</i> ( <i>HIF2α</i> ) associated with low hemoglobin concentration in Tibetan highlanders
|Proceedings of the National Academy of Sciences|2010|854
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study
|The Lancet|2016|485
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337